Biodegradable Polymer Implants With Diffusion-Controlled Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing implantable polymer systems for drug delivery suffer from a lack of controlled, sustained release mechanisms, often resulting in a burst release of therapeutic agents upon contact with physiologic fluids, which can be undesirable for clinical applications requiring prolonged and controlled drug delivery.
Innovation Solution
The development of biodegradable polymer implants with a control region and therapeutic region, where a releasing agent dissolves in vivo to form diffusion openings, allowing for a sustained and controlled release of therapeutic agents, such as analgesics, over an extended period, typically 7 to 14 days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If hydrophilic polymers are added as wetting agents to accelerate drug release, then immediate drug release is enhanced, but controlled sustained release is lost
Solution Approach 1:
The polymer carrier is segmented into distinct hydrophilic and hydrophobic regions. The hydrophilic regions facilitate initial wetting and drug release, while the hydrophobic regions maintain structural integrity and enable sustained release over time. This spatial segmentation resolves the contradiction by allowing different regions to perform different release functions simultaneously.
Solution Approach 2:
Different regions of the polymer carrier are assigned different properties: hydrophilic regions are localized to facilitate initial drug release and wetting, while hydrophobic regions are localized to provide structural stability and controlled sustained release. This local differentiation allows the system to achieve both rapid initial release and prolonged sustained release without compromise.
2Speed
If a burst release mechanism is used to provide immediate drug delivery, then rapid therapeutic effect is achieved, but systemic side effects increase
Solution Approach 1:
The polymer carrier creates localized hydrophilic regions that facilitate controlled initial drug release directly at the implant site, while hydrophobic regions maintain the drug within the carrier matrix. This local differentiation ensures that the burst release is confined to the immediate treatment area, reducing systemic exposure and associated side effects while still providing rapid therapeutic effect at the target location.
3Ease of operation
If biodegradable polymers are used for implantable drug delivery, then localized delivery is achieved, but core acidification occurs causing inflammation
Solution Approach 1:
The polymer carrier employs localized hydrophilic and hydrophobic regions that work together to control drug release without requiring extensive degradation. The hydrophilic regions facilitate controlled release through dissolution and diffusion, while hydrophobic regions maintain structural integrity longer, reducing the overall degradation rate and consequently minimizing core acidification and associated inflammation at the implant site.
Solution Approach 2:
The patent modifies the polymer composition parameters by incorporating both hydrophilic and hydrophobic segments with specific ratios and molecular weights. This parameter optimization controls the degradation rate and acidification process, enabling localized delivery while minimizing harmful inflammatory responses from core acidification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The implants achieve a controlled, sustained release of therapeutic agents, with specific release profiles tailored to minimize initial burst release and maximize prolonged efficacy, reducing systemic side effects and enhancing clinical effectiveness.
Implementation Method 1
a releasing agent configured to dissolve when the implant is placed in contact with a fluid to form diffusion openings
Implementation Method 2
form diffusion openings in the control region... release the therapeutic agent at the treatment site
Data Source
AI summary
The present technology relates to polymer implants. In some embodiments, the polymer implant may have a volume having minimum cross-sectional dimension of 400 μm. The polymer implant may be configured to be implanted within a mammalian body for at least 3 days without undergoing core acidification.